New drug cocktail aims to keep prostate cancer away after surgery

NCT ID NCT07444983

Not yet recruiting Disease control Sponsor: Fujian Medical University Union Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug rezvilutamide, combined with standard hormone therapy, can prevent high-risk prostate cancer from coming back after surgical removal. About 33 participants will take the pills and get injections for up to 2 years. The main goal is to see how many stay cancer-free for 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rezvilutamide (a drug taken orally) and leuprorelin (a hormone therapy injection)
What this could lead to: If it works, this could help prevent high-risk prostate cancer from returning after surgery, offering a new option to keep patients cancer-free longer.
What could go wrong: This is a small, early exploratory study with only 33 people, so results may not apply broadly. The treatment lasts 2 years and may cause side effects like fatigue, hot flashes, or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Department of Urology, Fujian Union Hospital, Fujian Medical University

Fuzhou, Fujian, 350000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.